The yellow fever vaccine is the only attenuated virus vaccine in which the recommendation for revaccination is every 10 years, indefinitely, without sound

scientific basis. The recommendation of a single vaccine dose for life is still controversial, and should probably await more convincing scientific evidence [13] and [14] before implementation. An alternative to consider is SB203580 cost that, similarly to other vaccines, primary and secondary yellow fever vaccine failures might occur and should discourage both the recommendation of a single dose for life and the need to wait 10 years for revaccination. In this study, the percentage of seropositive subjects and the GMTs of anti-yellow fever antibodies were substantially lower at 5 years post-vaccination when selleck chemicals llc compared with the newly vaccinated subjects (up to 45 days), and continued decreasing, albeit slightly, up to 10–11 years post-vaccination. The rate of seropositivity in the newly vaccinated subjects (93.6% with titres ≥2.9 log10 IU/mL) was slightly lower than in other studies involving adults: 96.0–98.0% [15] and [16]. A decreasing trend in neutralising antibody titres had been reported in 1948 in Brazilian vaccinees of various age groups, among whom 87% and 72% were reactive (intraperitoneal protection test in adult mice) at 2 and 6 years post-vaccination,

respectively) [17]. A pronounced decrease

in the first 5 years post-vaccination was also shown in 1999 in German vaccinees 10–79 years old [18]. Among those volunteers vaccinated for 11–38 years, 25.5% had neutralising antibodies (PRNT) ≤1:10. In 2008, Colombian volunteers aged 1–76 years were shown to have their seropositivity rates (titres > 1:10, PRNT) decreased from 97.1% among subjects that had been vaccinated for less than 1 year to 68.4% with 4 or more years post-vaccination [16]. Conversely, 95% of subjects vaccinated at the Pasteur Institute for over 10 years had antibody titres detected by PRNT [19]. Volunteers were over 60 years of age Rolziracetam and vaccination time was inferred for some of them, without mention of the number of doses. A study performed in a randomly selected population 16–83 years old, based on travel vaccination records of residents in Recife, Brazil, where there is no yellow fever transmission, reported that the mean neutralising antibody titres by PRNT were higher in 20 subjects vaccinated for 5 years than in 20 subjects vaccinated for 10 years. All subjects were seropositive (PRNT), whereas 60% and 55%, respectively, were IgG positive [20]. However, it was not mentioned the possibility that the subjects might have travelled to regions susceptible to disease transmission (with potential for natural boosting) or might have received more than a single vaccine dose.